photovoltaic doubled between 2011 and 2013. It's on an exponential growth curve. Think hockey stick. It's the cost that's driving PV. It's simply getting cheaper than steam turbine generation.
If the clamp study was good enough to warrant changing the description to ultra fast acting wouldn't SNY want to keep the drug? Or alternately wouldn't they want to keep someone else from having it,or have they done enough damage already to keep it off the market?
pass out vouchers for cartridges to trained volunteers.
PV power production is doubling every 2 years. By 2050 PV is expected to be the largest source of electric power worldwide. The average U.S. price for solar has plummeted from about 15 cents per kilowatt-hour a decade ago to about 5 cents today, according to the Lawrence Berkeley National Laboratory in California. This is Moore's law redux. Get in front of it.
His company, Retrophin. From bloomberg: " The name refers to “recombinant dystrophin,” Shkreli’s initial product idea for an engineered form of a protein that’s lacking in patients with a type of muscular dystrophy. Self-trained in biology, he says he wrote the genetic sequence himself for recombinant dystrophin after reading copious academic literature on the topic. One day he plans to manufacture the drug. Meanwhile, Retrophin has been acquiring the rights to obsolete remedies Shkreli says can be put to new and lucrative purposes."
Until it breaks those lines there's no *new* support and resistance. It tested resistance yesterday forming a double top. This is after forming a distinct bottom over several days. I'm looking for a classic cup and handle to suggest a breakout to the upside.
12 patients are required to have a 90% chance of detecting, as significant at the 5% level, an increase in the primary outcome measure from 0% in the control group to 67% in the experimental group.